Positive off-target safety assessment of EmtinB
Filed with ASX · · 2 pages · English
Neuroscientific Biopharmaceuticals Ltd. on 6ix
Story so far
Earlier from Neuroscientific Biopharmaceuticals
- Positive results in biomarker characterisation of Emtins
- Completion of Safety Pharmacology Studies
- NSB Receives R&D Advance & Overseas Finding
- Positive Results in Multiple Sclerosis Study
- 2021 Annual Report and Appendix 4E
Later from Neuroscientific Biopharmaceuticals
- Successful completion of key studies in lead up to Phase I
- NSB 1HY22 Key Activity Highlights
- New data demonstrates EmtinB activity in autoimmune diseases
- Positive safety result supports advance to clinical trials
- HREC Submission for early-phase Clinical Trial
Follow Neuroscientific Biopharmaceuticals into a list and get an email when it puts out news.
Follow Neuroscientific Biopharmaceuticals